PMID- 37522680
OWN - NLM
STAT- MEDLINE
DCOM- 20231023
LR  - 20231023
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 27
IP  - 14
DP  - 2023 Jul
TI  - Efficacy of switching from basal-bolus insulin therapy to twice-daily insulin 
      degludec/insulin aspart co-formulation plus insulin aspart in patients with 
      poorly controlled type 2 diabetes.
PG  - 6691-6699
LID - 33139 [pii]
LID - 10.26355/eurrev_202307_33139 [doi]
AB  - OBJECTIVE: The aim of this study was to evaluate the efficacy of twice-daily 
      (BID) insulin degludec/insulin aspart (IDegAsp) co-formulation + once-daily (OD) 
      bolus insulin aspart (IAsp) injection (IDegAsp BID-Plus) as simplified intensive 
      insulin therapy in patients with poorly controlled type 2 diabetes mellitus 
      (T2DM) with basal-bolus insulin therapy (BBIT). PATIENTS AND METHODS: The 
      retrospective study included 155 patients who switched from BBIT to IDegAsp 
      BID-Plus. After the initiation of the treatment, 73 patients continued regular 
      follow-up and insulin doses, number of injections, hemoglobin A1c (HbA1c) levels, 
      and other parameters were recorded from their files at baseline, 24, and 52 
      weeks. RESULTS: The mean age of the study population was 54.3+/-10.2 years, the 
      duration of T2DM was 9.7+/-5.7 years, fasting plasma glucose (FPG) was 252.7+/-66.7 
      mg/dl, and HbA1c levels were 10.5+/-1.5%. Among the included patients, 15 patients 
      received five injections, 51 patients received four injections, and 7 patients 
      received three injections per day. There was a significant decrease in HbA1c 
      (respectively; 10.46+/-1.54%, 7.97+/-1.24%, 7.98+/-1.23%, baseline and 6th-month 
      p<0.001, baseline and 12th-month p<0.001), FPG (respectively; 251.6+/-66.5 mg/dl, 
      136.1+/-34.7 mg/dl, 125.4+/-67.0  mg/dl, baseline and 6th-month p<0.001, baseline and 
      12th-month p<0.001) and daily dose of insulin (respectively; 102.9+/-29.0 Unit, 
      73.2+/-18.2 U,  63.7+/-20.3 Unit, baseline and 6th-month p<0.001, baseline and 
      12th-month p<0.001) at the end of week 24 and 52. CONCLUSIONS: Based on 
      real-world data, this study demonstrated that IDegAsp BID-Plus treatment provides 
      rapid and sustainable blood glucose control with lower insulin doses and fewer 
      injections than previous intensive insulin therapy.
FAU - Gunes, E
AU  - Gunes E
AD  - Department of Endocrinology, Metabolism and Diabetes, Health Sciences University, 
      Bursa State Hospital, Bursa, Turkey. drelifgunes@gmail.com.
FAU - Gunes, M
AU  - Gunes M
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 54Q18076QB (insulin degludec)
RN  - 0 (Hypoglycemic Agents)
RN  - D933668QVX (Insulin Aspart)
RN  - 0 (Glycated Hemoglobin)
RN  - 0 (Insulin)
RN  - 0 (Blood Glucose)
SB  - IM
MH  - Humans
MH  - Adult
MH  - Middle Aged
MH  - Hypoglycemic Agents
MH  - *Diabetes Mellitus, Type 2
MH  - Insulin Aspart/therapeutic use/adverse effects
MH  - Glycated Hemoglobin
MH  - Retrospective Studies
MH  - *Hypoglycemia/chemically induced
MH  - Insulin/therapeutic use
MH  - *Autoimmune Diseases/drug therapy
MH  - Blood Glucose
EDAT- 2023/07/31 13:09
MHDA- 2023/10/23 00:44
CRDT- 2023/07/31 08:53
PHST- 2023/10/23 00:44 [medline]
PHST- 2023/07/31 13:09 [pubmed]
PHST- 2023/07/31 08:53 [entrez]
AID - 33139 [pii]
AID - 10.26355/eurrev_202307_33139 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2023 Jul;27(14):6691-6699. doi: 
      10.26355/eurrev_202307_33139.